Refractory hypertension
Keywords:
resístant hypertensíon, treatment, complianceAbstract
Hypertension is one of the most important risk factor in the increase of morbidity and mortality of cardiovascular disease. Antihypertensive treatment reduces rísk not only for stroke but also for other cardiovascular díseases, despíte the use of the correct antihypertensive agents and the guidelines for there management a Jarge group of patíents faíl to achieve an effective blood pressure control.
The term resistant hypertensíon is frequently used when any hypertension has not been controlled adequately but it is very ímportant to dístínguíshed the true resistant hypertension from others forms of hypertension like the pseudohypertension, or secondary hypertensíon because it could Jead to the initiation of unnecessary treatment and potentíally adverse consequences, without forgetíng the ínappropríate therapy and a bad pMient compliance.
Resístant hypertension could became a Jess frequent problem with the ímprovement of antihypertensive drugs and ín most patients ít is possible to achíeve normotensíon with tripie drug regimen.
Downloads
References
Julius S. Curonary disease in hipertension: a new mosaic. J Hypertension. 1997: 15 1 suppl 2) : 3-10
Mac Mahou S. Peta R. Cutler J et al. Blood pressure. stroke and coronary hearth disease. Prolonged differences in blood pressure: prospective observational studies conector for the regression dilution bias. Lancet 1990: 335: 765-774
U.S. Renal Data System. USRDS 1997 Annual report. Bethesda Md: US Dept of Health and Human Services. National lnstitute of Diabetes and Digestive and kidney Disease: 1997
Klag MJ. Whelton PK. Randall BL. Neaton JD. Brancati FL. Ford CE. Sulman NB. Stamler J N Engl J Med 1996: 334: 13-18
Mac Lean DR et al. Overview of the epidemiological baseline indicators. ln: Morgenstern. W et al. Ecl. CINDIOFFICE for Europe. 1991: 11-35
Dobrossy. Elevated blood pressure. ln Dobrussy Ed. Prevention in primary care. Recommendations for promuting good practaci CINDI 2000 WHO Regional office for Europe Copenhagcn 1994: 43-51
Joint National Committee on detection. Evaluation and Treatment of high blood pressure. The fifth report of the Joint national Committee on Detection. Evaluation and Treatment of high hoold pressure (JNCY). Arch lntern Med 1993: 153: 15-1-18.1
The sixth Report of the Joinl National Committee on Prevention. Detection. Evaluation and Treatment of high hlood pressure. Arch Inter Med 1997: 157: 241.1-2446
Bobrie G. Coville P. Hypertension arterielle resistente. Arch Mal Cocur Vaiss 1995: 88: 1183-1185
Setaro FJ. Black RH. Refractory hypertension current concepts. N Engl J Med 1992: 327: 543-545
Szombathy T. Szalai C. Katalin B. Palicz T. Romics L. Csaszar A. Assotiationa of angiotensin II type I receptor polymorphism with resistant essencial hypertension. Cin Chim Acta 1998: 269: 91-100
Delanghe JR. Duprez DA. De Buyzere MI. Bergez BM. Claey, LR. Lerou-Roels GG. Clement DL. Rcfractory hypertension is associatcd with the haptoglobin 2-2 phenotype. J Cardiovase Risk 1995: 2: 131-136
Me Alister FA. Lewanazuk RZ. Teo KK. Resistant hypertension: an overview. Can J Cardiol 1996: 9: 822-828
Toner JM. Close CF. Ramsay LE. Factor, related to treatment resistance in hypertension. Q J Med 1990: 283: 1195-1204
Frohlich ED. Classification of resistant hypertension. Hypertension 1988: 11 (suppl II) 67-70
Sackett DL. Haynes RB. Gihsar ES et al. Randomized clinical trial of strategies for improving medication compliance in primary hipertension. Lancet 1975: 290: 1205-1207
Report of NHLBI Working Group- Managemenl of patients compliance in treatment of hypertension. Hypertension 1982: 4: 415-423
Miller NH. Hill M. Kottkc T. Ockene IS. The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professional. Circulation 1997: 95: 1085-1090
Yakovlevitch M. Black HR. Resistant hypertension in a tertiary care clinic. Arch Inter Med 1991: 151: 1786-1792
Braz Nogueira J. Hipertensão arterial resistente: abordagem terapêutica. Acta Médica portuguesa 1983: 4: 91-96
Carmona J. Amado P. Vasconcelos N. Santos 1. Pinto C. Forte G. Arsénio A. Nazaré J. Hipertensão da bata branca: variante da normalidade ou de hipertensão. Rev Port Cardiol 1998: 17: 505- 512
Prisant LM. Ambulatory blood pressure monitoring in the diagnosis of hypertension. Cardiol Clin 1995: 13 ( suppl 4 ): 479-490
Grin JM. McCabe EJ. White WB. Managemenl of hypertension after ambulatory hlood pressure monitoring. Ann lntern Med 1993: 118: 833-837
Brown MJ. Dickerson JE. Alpha-hlockade and calcium antagonism: an effective and well tolerated combination for the treatment of resistant hypertension. J Hyperten 1995: 6: 701-707
Dees A. Kremer HT. Breed JG. Verstapplen VM. puister SM. Meems Z. Calcium antagonists a useful additional therapy in treatment resistant hypertension: comparasion of felodipine ER anel nifedipine retard by 24H ambulatory blood pressure monitoring. Neth J Med 1997: 50: 2-12
Weher MA. Comparison of type I angiotensin ll receptor blocker, and angiotensin converting enzyme inhibitors in the treatment of hypcrtension. J Hypertens 1997: 15 (suppl ): 31-36
Gurcon P. Compliance and the chronotherapy of refractory arterial hypertension. Recenti Prog Med 1997: 88: 463-469
Additional Files
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
